A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern ...
Study Question: What is the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival in acute decompensated heart failure (ADHF)? Methods: The Survival of ...
A recent study utilized a machine learning-based approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF). A recent study ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
Please provide your email address to receive an email when new articles are posted on . Device-based thoracic duct decompression reduced congestion safely in patients with acute decompensated heart ...
Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle ...
GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech company pioneering a new treatment paradigm for acute decompensated heart failure (ADHF), today announced primary ...
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart Failure (HF) is one of the leading problems in cardiology practice today. Acute decompensated heart ...
The Texas Heart Institute at Baylor St. Luke's Medical Center Cardiovascular Disease Fellow Dr. Matthew Segar co-authored a study in JACC Heart Failure led by his research and residency mentor, ...
A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results